Immuneering Corporation racks up $17 mln Series A

Immuneering Corporation, a developer of cancer medicines, has closed $17 million in Series A financing.

Immuneering Corporation, a developer of cancer medicines, has closed $17 million in Series A financing. Boxcar PMJ LLC led the round. Concurrent with the financing, Boxcar’s founding partner Joseph Kekst will join Immuneering’s board of directors and Boxcar’s founding partner Peter Feinberg will join as an observer.

Source: Press Release